Total Parenteral Nutrition: The Long and The Short of It

Duna Penn

Introduction

Within 30 years of Harvey's discovery of the circulatory system, attempts were made to utilize intravenous routes for nutrient administration. In 1656, Sir Christopher Wren infused wine into the veins of dogs via goose quills attached to a pig's bladder. Over the ensuing years, salt and sugar solutions, milk, olive oil, egg whites, and in later times, protein hydrolysates were tried with varying degrees of success. However, it was not until the 20th century that total parenteral nutrition (TPN) began to be viewed as a realistic therapeutic modality, stimulated by Wilmore and Dudrick's report of normal growth in a young infant with extensive intestinal atresia who was successfully maintained on intravenous nutrition for over 6 weeks. Since then, there have been many advances and refinements, including the development of specialized crystalline amino acid solutions and lipid emulsions. Further investigation is currently underway to determine the effect of "medical foods", i.e., specialized nutrients targeted for specific purposes, e.g., glutamine for immunomodulation and intestinal mucosal preservation.

TPN is now commonly used for providing nutritional support in a variety of conditions associated with intestinal dysfunction or other causes of inability to provide adequate enteral nutrition. However, with time and experience, the initial enthusiasm for this method has been tempered by the realization that bypassing the gastrointestinal tract during delivery of nutrients is unphysiological and may have various side effects. The 2 most concerning clinical entities are TPN-associated liver dysfunction and metabolic bone disease.

Accepted for publication: December 13, 1995. Author's address: Duna Penn, MD, MS. Department of Pediatrics, Louisiana State University, New Orleans, USA.
Hormonal Effects

Extrauterine existence is characterized by intermittent feeding and fasting. Food intake usually occurs during wakefulness, fasting during sleep. These feed-fast and wake-sleep pattern are associated with secretory rhythms of various circulating hormones.\(^5\)

Continuous or cycled night-time infusion of nutrients, as well as the types of nutrients infused, have been shown to cause hormonal perturbation, most notably a hyperinsulinism\(^6\) and suppression of growth hormone.\(^7\) The significance of these effects is controversial in view of the well-documented success of TPN in reversing growth failure.

Intestinal Effects

The absence of enteral feeding is associated with a number of effects upon the gastrointestinal tract.\(^8\) The etiology of these effects is probably multifactorial, involving lack of postprandial exposure to local mechanical stress, luminal dietary nutrients and trophic factors. Nutrients in the gut stimulate trophic pancreatic/biliary secretions, gut hormones and neurovascular reflexes. In animals, TPN was associated with a fairly rapid onset of small intestinal hypoplasia\(^9\) and decreased disaccharidase activities.\(^10\) These adverse effects or secretin.\(^12\) Colonic mucosal atrophy has also been described.\(^9\)

In the human, perturbations due to TPN are particularly evident during early development. Plasma concentrations of various gut hormones (including gastrin, cholecystokinin, secretin, gastric inhibitory peptide, neurotensin motilin, and enteroglucagon) were decreased in preterm infants who had never received enteral feedings.\(^13\) Longitudinal manometry demonstrated that the development of mature intestinal motility patterns in the very premature infant is delayed by lack of enteral intake.\(^15\) TPN without enteral feeding results in impaired intestinal mucosal growth, as well as biochemical and functional maturation.\(^16\) These findings are reversible with even small amount of enteral feedings. In adults, intestinal hypoplasia appears to be variable, but decreased disaccharidase activity has been reported.\(^17\)

Exocrine Pancreatic Effects

The exocrine pancreas is strongly stimulated by digestion products of proteins and fats. Animal studies have reported conflicting effects of intravenously administered amino acids and fatty acids upon the pancreas. However, exocrine pancreatic function in the human does not appear to be stimulated significantly by TPN,\(^8\) which is proven to be useful in the treatment of pancreatitis. The long term implications need to be clarified.
Hepatobiliary Effects

Biliary "sludge" and gall stones have been reported in both children and adults on TPN, suggesting bile stasis. TPN-associated cholestasis was initially observed in a preterm infant who exhibited cirrhosis, bile duct proliferation and centrilobular cholestasis at the time of death after 71 days of TPN. Since then, numerous reports have appeared describing an association between TPN and cholestatic liver disease. The incidence has varied from 7-57%. Although found in both children and adults, it is most commonly a disease of infants increasing in frequency with decreasing gestation age and birth weight and with increasing duration of therapy. The etiology is probably multifactorial (Table 1).

Although none of the factors listed in Table 1 have been confirmed as causal factors, a reasonable working hypothesis might involve hepatocytes various hepatotoxic insults, e.g. poorly metabolizable amino acids, secondary bile acids, bacterial endotoxins, and slowly develop hepatic damage. The diagnosis is one of exclusion in an individual with conjugated hyperbilirubinemia who has received TPN for more than a week. Elevated total serum bile acids or cholic acid conjugates, gamma-glutamyl transpeptidase or 5'-nucleotidase have been suggested as early indicators. Serum transaminases and alkaline phosphatase may be less valuable due to non-specificity and late occurrence. Evidence of compromised hepatic function, e.g. decreased serum albumin, prolonged prothrombin time, and also hyperammonemia are signs of impending hepatic failure.

Characteristic but non-specific histologic signs include canalicular, hepatocyte and Kupffer cell cholestasis, bile duct proliferation, perportal inflammation and/or portal fibrosis. Treatment of choice is prevention by limitation of TPN duration, aggressive institution of enteral nutrition, avoidance of hypercaloric alimentation, use of infant-adapted (taurine-supplemented) amino acid solutions. Abnormal liver function is indication for discontinuing parenteral and instituting enteral nutrition. this usually results in rapid improvement. If TPN cannot be stopped, efforts should be made to avoid hypercaloric intake, undertake TPN cycling, and initiate low-dose enteral feedings. Treatment of bacterial overgrowth may be helpful in infants with short gut syndrome. Supplementation of TPN to intake have been suggested. Choleretic agents such as phenobarbital, ursodeoxycholic acid as well as cholecystokinin analogues have also been used. Infants with short gut syndrome have the highest risk for progression to end-stage liver disease.

Bone Effects

Metabolic bone disease is a well-recognized complication of long term (months to years) parenteral nutrition in both children and adults. In children, it is often diag-
Table 1. Risk factors for the development of TPN-associated cholestatic liver disease

<table>
<thead>
<tr>
<th>General risk factors</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prematurity</td>
<td>hepatobiliary immaturity</td>
</tr>
<tr>
<td>• lack of enteral feeding</td>
<td>bile flow, gut motility</td>
</tr>
<tr>
<td>• sepsis</td>
<td>bile flow</td>
</tr>
<tr>
<td>• short gut</td>
<td>bacterial overgrowth</td>
</tr>
<tr>
<td>• lithocholic acid</td>
<td>gut inflammation, surgery</td>
</tr>
<tr>
<td>• gut motility,</td>
<td>bacterial overgrowth</td>
</tr>
<tr>
<td>Potentially toxic factors in TPN</td>
<td></td>
</tr>
<tr>
<td>• improper dextrose load</td>
<td>bile flow</td>
</tr>
<tr>
<td>• hypercaloric alimentation</td>
<td>hepatic dysfunction</td>
</tr>
<tr>
<td>• amino acids</td>
<td>bile flow, e.g. sulfur-cont,aromatic hepatotoxicity</td>
</tr>
<tr>
<td>• trace minerals (Cu,Mn,W)</td>
<td>hepatotoxicity</td>
</tr>
<tr>
<td>Potential deficiencies with TPN</td>
<td></td>
</tr>
<tr>
<td>• taurine</td>
<td>abnormal bile acid conjugation</td>
</tr>
<tr>
<td>• choline</td>
<td>steatosis in rats</td>
</tr>
<tr>
<td>• carnitine</td>
<td>fatty acid oxidation, detox. ofacyl groups</td>
</tr>
<tr>
<td>• selenium</td>
<td>detoxification of oxygen radicals</td>
</tr>
<tr>
<td>• molybdium</td>
<td>detoxification of sulfur-containing a. acids</td>
</tr>
</tbody>
</table>

nosed by serial biochemical (alkaline phosphatase) or roentgenographic examination (osteopenia, rickets, fractures) as well as by clinical evidence of fractures. In adults, chief complaints include back pain, periaricular cone pain and fractures. Paradoxically, the condition is most apparent as nutritional status improves, i.e. during weight gain and "catch-up" growth. The exact frequency is unknown but the entity appears to be quite common with prolonged TPN. The etiology is unclear although a number of potential factors have been identified (Table 2). In premature infants, the major issue is clearly one of inadequate provision of calcium and phosphate. It is difficult to duplicate the efficiency of the human placenta as a delivery system. many of these infants receive chronic diuretic therapy, e.g., furosemide, that leads to Table 2. Factors implicated in metabolic bone disease increased urinary loss of calcium. In adults, there are more questions than answers due to the multiplicity of confounding factors. In particular, early problems with aluminum toxicity have muddled the picture. It is unclear whether bypassing the normal intestinal regulation of calcium/ phosphate homeostasis and providing a continuous influx of calcium and phosphate leads to metabolic bone disease.
Table 2. Factors associated with bone alterations in chronic TPN

**Inadequate supply of calcium and phosphorus**
- requirements of preterm infants
- limited solubility in TPN solutions
- inappropriate calcium/phosphorus ratio

**Increased urinary calcium loss**
- volume expansion (cyclic TPN)
- amino acid intake
- calcium intake
- inadequate phosphate intake
- aluminium toxicity
- chronic diuretic therapy (e.g. furosemide)

**Increased urinary phosphate loss**
- glucose intake
- phosphate intake

**Effects on bone matrix formation/bone mineralization**
- ammonium toxicity (contaminant of minerals, casein hydrolysate)
- exaggerated in face of renal impairment
- sensitivity to exogenous Vit D?
- other factors?
  - high dose heparin
  - acetate
  - metabolic acidosis
  - unknown micronutrients?

---

**Renal Effects**

Although short-term TPN has been shown to increase creatinine clearance, disturbing data has recently been reported concerning impaired renal function in both children and adults on long-term TPN. Creatinine clearance decreased between 0.6%-15.4% in 29 out of 33 adult TPN patients on long-term TPN (duration: 8.3±4.4 years; >70% of nutrition needs); Average rate of decline was 3.5% per year. The decrease of glomerular filtration rate was greater than that expected for age in patients who had received TPN >10 years. Tabular reabsorption of phosphate was impaired in 52% of subjects and correlated with glomerular filtration rate and estimated creatinine clearance. These decreases in glomerular and tubular function could not be totally cx-
plained by advancing age, nephrotoxic drug use or septic episodes and appeared to be unrelated to intravenous amino acid intake. The authors speculate that acid loading from TPN may play a role. The etiology is unclear at this time.

References


